Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770809 | 0.80 | ACE (0.54) | ACEACE2ALDH1A1 | |
| SCHEMBL15386652 | 0.80 | ACE (0.54) | ACEACE2ALDH1A1 | |
| SCHEMBL770240 | 0.80 | ACE (0.54) | ACEACE2ALDH1A1 | |
| SCHEMBL771602 | 0.79 | ACE (0.49) | ATML3MBTL1KMT2AACEACE2 | |
| SCHEMBL17690709 | 0.79 | TRPV1 (0.46) | — | |
| SCHEMBL10138268 | 0.78 | ACE (0.55) | KMT2AACEACE2ALDH1A1 | |
| SCHEMBL772162 | 0.78 | UGCG (0.44) | NPSR1ACEACE2ALDH1A1 | |
| SCHEMBL772411 | 0.78 | NPC1 (0.43) | ATML3MBTL1KMT2AACEACE2 | |
| SCHEMBL803113 | 0.78 | NPC1 (0.43) | ATML3MBTL1KMT2AACEACE2 | |
| SCHEMBL770465 | 0.77 | DPP4 (0.45) | HDAC1HDAC6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HDAC1 301/4885HDAC6 2405/4885ATM 3373/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HDAC1 304/4885HDAC6 2411/4885ATM 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.